<SEC-DOCUMENT>0001213900-26-077127.txt : 20260710
<SEC-HEADER>0001213900-26-077127.hdr.sgml : 20260710
<ACCEPTANCE-DATETIME>20260710160200
ACCESSION NUMBER:		0001213900-26-077127
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260706
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260710
DATE AS OF CHANGE:		20260710

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InMed Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001728328
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39685
		FILM NUMBER:		261168731

	BUSINESS ADDRESS:	
		STREET 1:		1445-885 WEST GEORGIA ST.
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C 3E8
		BUSINESS PHONE:		(604) 669-7207

	MAIL ADDRESS:	
		STREET 1:		1445-885 WEST GEORGIA ST.
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C 3E8
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0297284-8k425_inmed.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:us-roles="http://fasb.org/us-roles/2026" xmlns:country="http://xbrl.sec.gov/country/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:INM="http://inmedpharma.com/20260706">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02F_US%2DGAAP%2D2026 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_INM_inmedpharma.com_20260706 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20260706_20260706 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001728328 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-07-06" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-07-06" id="Fact000004" name="dei:EntityCentralIndexKey">0001728328</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="inm-20260706.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-07-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001728328</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-07-06</xbrli:startDate>
        <xbrli:endDate>2026-07-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20260706__20260706_zlGTX6acDiAg"><ix:nonNumeric contextRef="AsOf2026-07-06" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_904_edei--DocumentPeriodEndDate_c20260706__20260706_zIz4g3NQRSc2"><ix:nonNumeric contextRef="AsOf2026-07-06" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">July 6, 2026</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityRegistrantName_c20260706__20260706_zevgFGsTzz2"><ix:nonNumeric contextRef="AsOf2026-07-06" id="Fact000011" name="dei:EntityRegistrantName">INMED PHARMACEUTICALS INC.</ix:nonNumeric></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20260706__20260706_zzxdfwarxXSj"><ix:nonNumeric contextRef="AsOf2026-07-06" format="ixt-sec:edgarprovcountryen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">British Columbia, Canada</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityFileNumber_c20260706__20260706_zmvA11IHmFg1"><ix:nonNumeric contextRef="AsOf2026-07-06" id="Fact000013" name="dei:EntityFileNumber">001-39685</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20260706__20260706_zJXEyBMipCIj"><ix:nonNumeric contextRef="AsOf2026-07-06" id="Fact000014" name="dei:EntityTaxIdentificationNumber">98-1428279</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction<br/>
of incorporation)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20260706__20260706_z1zR5gSRFIJ3"><ix:nonNumeric contextRef="AsOf2026-07-06" id="Fact000015" name="dei:EntityAddressAddressLine1">Suite 1445 &#8211; 885 West Georgia St.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityAddressCityOrTown_c20260706__20260706_zuaeS3leUeo2"><ix:nonNumeric contextRef="AsOf2026-07-06" id="Fact000016" name="dei:EntityAddressCityOrTown">Vancouver</ix:nonNumeric></span>, British Columbia, <span id="xdx_901_edei--EntityAddressCountry_c20260706__20260706_zli7t1cVaaVd"><ix:nonNumeric contextRef="AsOf2026-07-06" format="ixt-sec:countrynameen" id="Fact000017" name="dei:EntityAddressCountry">Canada</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20260706__20260706_zPCZCZtvtZQ4"><ix:nonNumeric contextRef="AsOf2026-07-06" id="Fact000018" name="dei:EntityAddressPostalZipCode">V6C 3E8</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices) (Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>(<span id="xdx_905_edei--CityAreaCode_c20260706__20260706_zI295FODhp3j"><ix:nonNumeric contextRef="AsOf2026-07-06" id="Fact000019" name="dei:CityAreaCode">604</ix:nonNumeric></span>) <span id="xdx_90C_edei--LocalPhoneNumber_c20260706__20260706_zAIGU12Pi8vi"><ix:nonNumeric contextRef="AsOf2026-07-06" id="Fact000020" name="dei:LocalPhoneNumber">669-7207</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--WrittenCommunications_c20260706__20260706_z380fEZa2SXh"><ix:nonNumeric contextRef="AsOf2026-07-06" format="ixt:booleantrue" id="Fact000021" name="dei:WrittenCommunications">&#9746;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--SolicitingMaterial_c20260706__20260706_zadcn35tMR"><ix:nonNumeric contextRef="AsOf2026-07-06" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--PreCommencementTenderOffer_c20260706__20260706_zbs52iigVOEk"><ix:nonNumeric contextRef="AsOf2026-07-06" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--PreCommencementIssuerTenderOffer_c20260706__20260706_zbUWL0Nzkutc"><ix:nonNumeric contextRef="AsOf2026-07-06" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20260706__20260706_zvFZ79DBtQt3"><ix:nonNumeric contextRef="AsOf2026-07-06" id="Fact000025" name="dei:Security12bTitle">Common Shares, no par value</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20260706__20260706_zIAPXtvA5A6a"><ix:nonNumeric contextRef="AsOf2026-07-06" id="Fact000026" name="dei:TradingSymbol">INM</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_903_edei--SecurityExchangeName_c20260706__20260706_zoWXfaN7IFYg"><ix:nonNumeric contextRef="AsOf2026-07-06" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_903_edei--EntityEmergingGrowthCompany_c20260706__20260706_z6G5TCxNZdQi"><ix:nonNumeric contextRef="AsOf2026-07-06" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#8201;1.01 Entry into a Material Definitive Agreement. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Amendment to Merger Agreement </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2026, InMed Pharmaceuticals Inc., a
company incorporated under the laws of the Province of British Columbia (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;), Indigo Merger Sub Corp., a
Delaware corporation and a wholly owned subsidiary of the Company (the &#8220;<span style="text-decoration: underline">First Merger Sub</span>&#8221;), Indigo Merger Sub II, LLC,
a Delaware limited liability company and a wholly owned subsidiary of the Company (the &#8220;<span style="text-decoration: underline">Second Merger Sub</span>&#8221; and, together
with First Merger Sub, the &#8220;<span style="text-decoration: underline">Merger Subs</span>&#8221;), and Mentari Therapeutics, Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Mentari</span>&#8221;),
entered into Amendment No. 1 to the Agreement and Plan of Merger and Reorganization (the &#8220;<span style="text-decoration: underline">Amendment</span>&#8221;), which amends
the Agreement and Plan of Merger and Reorganization, dated as of May 19, 2026 (as amended, the &#8220;<span style="text-decoration: underline">Merger Agreement</span>&#8221;),
by and among the Company, the Merger Subs, and Mentari.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A description of the Merger Agreement prior to
the Amendment and the transactions contemplated thereby (the &#8220;<span style="text-decoration: underline">Merger</span>&#8221;) was previously reported in the Current Report
on Form 8-K filed by the Company with the Securities and Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;) on May 19, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Amendment (i) clarifies the sequencing of
the Contemplated Transactions (as defined in the Merger Agreement), including by providing that the Company will effect a name change
to &#8220;Mentari Therapeutics, Inc.&#8221; prior to the Closing Date (as defined in the Merger Agreement) and will redomesticate from
the Province of British Columbia to the State of Nevada on the Closing Date but prior to the filing of the certificate of merger, and
will effect the Nasdaq Reverse Split (as defined in the Merger Agreement), if any, prior to the First Effective Time (as defined in the
Merger Agreement); (ii) introduces the concept of a Company PIPE Amendment (as defined in the Merger Agreement) to facilitate potential
additional private placement financing of Mentari pre-closing and clarifies the impact of such additional potential financing on the Exchange
Ratio (as defined in the Merger Agreement); and (iii) clarifies the intended tax treatment of the Merger by, among other things, removing
the contingency relating to a potential redomestication of the Company to the Cayman Islands and confirming that the First Merger and
the Second Merger (as such terms are defined in the Merger Agreement), taken together, are intended to constitute an integrated transaction
that qualifies as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as expressly modified by the Amendment,
all terms and conditions of the Merger Agreement remain in full force and effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing summary of the Amendment does not
purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 2.2
to this Current Report on Form 8-K and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item&#8201;7.01 Regulation FD Disclosure.
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2026, the Company and Mentari issued
a joint press release announcing the entry into the Amendment, as well as the filing on July 2, 2026 of a registration statement on Form
S-4 (the &#8220;<span style="text-decoration: underline">Form S-4</span>&#8221;) containing a preliminary joint proxy statement/prospectus and management information circular
with the SEC in connection with the proposed transaction contemplated therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The press release is furnished as <span style="text-decoration: underline">Exhibit 99.1</span>
to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced
in the press release is not incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Item 7.01, including <span style="text-decoration: underline">Exhibits
99.1</span>, attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the &#8220;<span style="text-decoration: underline">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;),or the Exchange Act,
except as expressly set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Forward-Looking Statements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K and the exhibits
filed or furnished herewith contain forward-looking statements (including within the meaning of Section 21E of the Exchange Act and Section
27A of the Securities Act) concerning the Company, Mentari, the proposed Merger and related matters. These forward-looking statements
include express or implied statements relating to the structure, timing and completion of the proposed Merger; the combined company&#8217;s
listing on Nasdaq after closing of the proposed Merger; expectations regarding the ownership structure of the combined company (including
the relative ownership the Company&#8217;s shareholders in the combined company); expectations regarding the pre-closing financing (and
additional proceeds thereunder, if any) and the closing thereof; the effectiveness of the Form S-4 and the timing of the special meeting
of the Company&#8217;s shareholders; the future operations of the combined company; the nature, strategy and focus of the combined company;
the development and commercial potential and potential benefits of any product candidates of the combined company; and other statements
that are not historical facts. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221;
&#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221;
&#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221;
&#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements
contain these identifying words.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These forward-looking statements are based on
current expectations and beliefs and are subject to risks and uncertainties, including risks related to the failure to obtain shareholder
approval, the failure to complete the pre-closing financing (as currently contemplated or as amended), the failure to satisfy other closing
conditions, delays in obtaining or adverse outcomes related to required regulatory approvals, the possibility that the Merger Agreement
may be terminated in accordance with its terms, the Company&#8217;s ability to maintain listing on Nasdaq, unexpected costs, charges or
expenses resulting from the proposed transaction, the effect of the announcement or pendency of the proposed transaction on existing and
potential business relationships, operating results and business generally, and the other risks and uncertainties described in the Company&#8217;s
filings with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements, and neither the
Company nor Mentari undertakes any obligation to update any forward-looking statement except as required by applicable law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>No Offer or Solicitation </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K and the exhibits
filed or furnished herewith are not intended to and do not constitute (i) a solicitation of a proxy, consent or approval with respect
to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for
or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there
be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be
made except by means of a prospectus meeting the requirements of the Securities Act or an exemption therefrom. Subject to certain exceptions
to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly,
in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by
any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign
commerce, or any facility of a national securities exchange, of any such jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION
HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS CURRENT REPORT ON FORM 8-K AND THE EXHIBITS FILED OR FURNISHED HEREWITH
ARE TRUTHFUL OR COMPLETE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Important Additional Information About the
Proposed Transaction Will be Filed with the SEC </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form 8-K and the exhibits
filed or furnished herewith are not substitutes for any other document that the Company may file with the SEC in connection with the proposed
transaction, including the Form S-4. In connection with the proposed transaction, the Company intends to file relevant materials with
the SEC, including the Form S-4, which has not yet been declared effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THE COMPANY URGES INVESTORS AND SHAREHOLDERS TO
READ THE REGISTRATION STATEMENT, INCLUDING THE PROXY STATEMENT/PROSPECTUS AND MANAGEMENT INFORMATION CIRCULAR CONTAINED THEREIN, AND ANY
OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN
THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, MENTARI, THE PROPOSED
TRANSACTION AND RELATED MATTERS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors and shareholders will be able to obtain
free copies of the Form S-4 and other documents filed by the Company with the SEC (when they become available) through the website maintained
by the SEC at <i>www.sec.gov</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Participants in the Solicitation </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, Mentari and their respective directors
and executive officers may be deemed to be participants in the solicitation of proxies from shareholders in connection with the proposed
transaction. Information about the Company&#8217;s directors and executive officers, including a description of their interests in the
Company is included in the Company&#8217;s most recent Annual Report on Form 10-K and subsequent reports filed with the SEC and certain
Canadian securities regulators. Additional information regarding such persons and their interests in the proposed transaction is included
in the Form S-4 and accompanying proxy statement/prospectus and management information circular relating to the proposed transaction
that is filed with the SEC, which has not yet been declared effective. These documents can be obtained free of charge from the sources
indicated above.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#8201;9.01 Financial Statements and Exhibits. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit<br/>
Number</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="ea029728401ex2-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No.1 to the Agreement and Plan of Merger and Reorganization, dated as of July 6, 2026, by and among InMed Pharmaceuticals Inc., Indigo Merger Sub Corp., Indigo Merger Sub II, LLC and Mentari Therapeutics, Inc.</span></a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="ea029728401ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, issued on July 6, 2026 </span></a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INMED PHARMACEUTICALS INC.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</span></td></tr>
  <tr>
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 35%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Eric A. Adams</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: July 10, 2026</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric A. Adams</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President &amp; CEO</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LbMd/sDudOgQp8gQ8ba4KMWtGWn9eyTf0rohhkBIzvlyhBiInJamRobjvCxgj01ba49Q4hkZ7QmDI1utUwizxItxnrX13foDMwoMBmYSj3W4d867cVilIKdDJYfJBJRMRwpmGxF99Yzs2VRovdE1aFvBjqllg17zq/+w10+y1Ly6pAOyM2RTULHs5TckUiWwpbt+EF8dFEUmokFXkciZbm1wLZ4e7ZeERY1NiHM9/e/oA8H7Sks= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.2
<SEQUENCE>2
<FILENAME>ea029728401ex2-2.htm
<DESCRIPTION>AMENDMENT NO.1 TO THE AGREEMENT AND PLAN OF MERGER AND REORGANIZATION, DATED AS OF JULY 6, 2026, BY AND AMONG INMED PHARMACEUTICALS INC., INDIGO MERGER SUB CORP., INDIGO MERGER SUB II, LLC AND MENTARI THERAPEUTICS, INC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 2.2</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Execution Version</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Amendment
No. 1 to the<BR>
Agreement and Plan of Merger AND REORGANIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This <FONT STYLE="text-transform: uppercase"><B>Amendment
No. 1 to Agreement and Plan of Merger and reorganization</B></FONT> (this &ldquo;<B><I>Amendment</I></B>&rdquo;) is made as of July 6,
2026, with respect to that certain Agreement and Plan of Merger and Reorganization (as amended to date, the &ldquo;<B><I>Merger Agreement</I></B>&rdquo;),
dated as of May 19, 2026 (the &ldquo;<B><I>Agreement Date</I></B>&rdquo;), by and among InMed Pharmaceuticals Inc., a corporation organized
under the laws of British Columbia, Canada (&ldquo;<B><I>Parent</I></B>&rdquo;), Indigo Merger Sub Corp., a Delaware corporation and wholly
owned subsidiary of Parent (&ldquo;<B><I>First Merger Sub</I></B>&rdquo;), Indigo Merger Sub II, LLC, a Delaware limited liability company
and wholly owned subsidiary of Parent (&ldquo;<B><I>Second Merger Sub</I></B>&rdquo;, and, together with First Merger Sub, &ldquo;<B><I>Merger
Subs</I></B>&rdquo; and each, a &ldquo;<B><I>Merger Sub</I></B>&rdquo;), and Mentari Therapeutics, Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;).
All capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>W I T N E S S E T H:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Whereas</B></FONT>,
pursuant to Section 11.2 of the Merger Agreement, the Merger Agreement may be amended by any instrument in writing signed on behalf of
the Company, Merger Subs, and Parent, with the approval of the respective boards of directors of the Company, Merger Subs, and Parent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Whereas</B></FONT>,
the Parent Board has (i) determined that the Contemplated Transactions (including as amended pursuant to this Amendment) are fair to,
advisable and in the best interests of Parent and its shareholders, (ii) adopted, approved and declared advisable the Merger Agreement
(including as amended hereby) and the Contemplated Transactions, including the issuance of Parent Shares to the shareholders of the Company
pursuant to the terms of the Merger Agreement (including as amended hereby), and (iii) determined to recommend, upon the terms and subject
to the conditions set forth in the Merger Agreement (including as amended hereby), that the shareholders of Parent vote to approve the
Merger Agreement (including as amended hereby) and thereby approve the Parent Shareholder Matters, including the Contemplated Transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Whereas</B></FONT>,
the First Merger Sub Board has (i) determined that the Contemplated Transactions (including as amended pursuant to this Amendment) are
fair to, advisable, and in the best interests of First Merger Sub and its sole stockholder, (ii) approved and declared advisable the Merger
Agreement (including as amended hereby) and the Contemplated Transactions, and (iii) determined to recommend, upon the terms and subject
to the conditions set forth in the Merger Agreement (including as amended hereby), that the stockholder of First Merger Sub votes to adopt
the Merger Agreement (including as amended hereby) and thereby approve the Contemplated Transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Whereas</B></FONT>,
the sole member of the Second Merger Sub has (i) determined that the Contemplated Transactions (including as amended pursuant to this
Amendment) are fair to, advisable, and in the best interests of Second Merger Sub and its sole member, (ii) approved and declared advisable
the Merger Agreement (including as amended hereby) and the Contemplated Transactions, and (iii) determined to recommend, upon the terms
and subject to the conditions set forth in the Merger Agreement (including as amended hereby), that the sole member of Second Merger Sub
votes to adopt the Merger Agreement (including as amended hereby) and thereby approve the Contemplated Transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Whereas</B></FONT>,
the Company Board has (i) determined that the Contemplated Transactions (including as amended pursuant to this Amendment) are fair to,
advisable and in the best interests of the Company and its stockholders, (ii) approved and declared advisable the Merger Agreement (including
as amended hereby) and the Contemplated Transactions, and (iii) determined to recommend, upon the terms and subject to the conditions
set forth in the Merger Agreement (including as amended hereby), that the stockholders of the Company vote to adopt the Merger Agreement
(including as amended hereby) and thereby approve the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>Now,
Therefore</B></FONT>, in consideration of the foregoing recitals, the mutual covenants and agreements set forth herein, and other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, intending to be legally bound, the Company,
Parent and Merger Subs hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="text-transform: uppercase"><B>Article
1&#9;Amendments to the Merger Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.1.</TD><TD STYLE="text-align: justify"><U>Company Valuation</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.1.1</TD><TD STYLE="text-align: justify">Section 1.1(a) of the Merger Agreement is hereby amended by adding the following defined terms in the
appropriate alphabetical order:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&ldquo;<B>Company
PIPE Amendment</B>&rdquo; means any amendment, amendment and restatement, joinder, supplement or other modification of the Subscription
Agreement effected following the Original Agreement Date that results in an increase to the amount of proceeds to be received from the
Company Pre-Closing Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&ldquo;<B>Original
Agreement Date</B>&rdquo; means May 19, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.1.2</TD><TD STYLE="text-align: justify">The definition of &ldquo;Company Equity Value&rdquo; shall be, and hereby is, amended and replaced in
its entirety with the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&ldquo;<B>Company
Equity Value</B>&rdquo; means $125,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.1.3</TD><TD STYLE="text-align: justify">The definition of &ldquo;Company Valuation&rdquo; shall be, and hereby is, amended and replaced in its
entirety with the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&ldquo;<B>Company
Valuation</B>&rdquo; means (i) the Company Equity Value, plus (ii) the amount of proceeds actually received by the Company from the Company
Pre-Closing Financing (including the proceeds actually received from any Company Notes (and any interest, premiums and fees thereon),
contributed as consideration in the Company Pre-Closing Financing), excluding the amount of any proceeds received pursuant to any Company
PIPE Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.1.4</TD><TD STYLE="text-align: justify">The definition of &ldquo;Company Outstanding Shares&rdquo; shall be, and hereby is, amended and replaced
in its entirety with the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&ldquo;<B>Company
Outstanding Shares</B>&rdquo; means, without duplication, the total number of shares of Company Capital Stock outstanding immediately
prior to the First Effective Time (including any shares of Company Common Stock or Company Preferred Stock that are issued in, or issuable
upon the exercise or conversion of securities issued in, the Company Pre-Closing Financing), expressed on a fully diluted and as-converted-to-Company
Common Stock basis assuming, without limitation or duplication, the exercise of all Company Options, Company RSUs, Company Warrants or
other rights or commitments to receive shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable
into shares of Company Common Stock or Company Preferred Stock, including the Company Notes), whether conditional or unconditional or
vested or unvested, that are outstanding as of immediately prior to the First Effective Time; provided that &ldquo;Company Outstanding
Shares&rdquo; shall exclude (i) any Company Options, Company RSUs, Company Warrants and any other equity awards issued under the Company
Stock Plan (including any shares of Company Common Stock issuable upon the exercise of such Company Options, Company Warrants or other
equity awards) issued to directors, employees, consultants or other service providers following the date hereof but prior to the Closing
(collectively, the &ldquo;Service Provider Grants&rdquo;), (ii) any shares of Company Common Stock underlying Company Notes that are to
be contributed as consideration in the Company Pre-Closing Financing pursuant to the Subscription Agreement (to avoid double counting),
and (iii) the total number of shares of Company Capital Stock that are issued pursuant to, or issuable upon the exercise or conversion
of securities issued pursuant to, any Company PIPE Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.2.</TD><TD STYLE="text-align: justify"><U>Continuation Mechanics</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.2.1</TD><TD STYLE="text-align: justify">The definition of &ldquo;Nasdaq Reverse Split&rdquo; shall be, and hereby is, amended and replaced in
its entirety with the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&ldquo;<B>Nasdaq
Reverse Split</B>&rdquo; means a reverse stock split of all outstanding Parent Common Shares, to be effected by Parent prior to the First
Effective Time for the purpose of maintaining compliance with Nasdaq listing standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.2.2</TD><TD STYLE="text-align: justify"><U>Section 2.3</U> of the Merger Agreement shall be, and hereby is, amended and replaced in its entirety
with the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">2.3.&#9;<U>Continuation; Closing; First
Effective Time; Second Effective Time</U>. Unless this Agreement is earlier terminated pursuant to the provisions of <U>Section 10</U>,
and subject to the satisfaction or waiver of the conditions set forth in <U>Section 7</U>, <U>Section 8</U> &lrm;and <U>Section 9</U>,
the consummation of the Merger (the &ldquo;<B>Closing</B>&rdquo;) shall take place remotely, as promptly as practicable (but in no event
later than the second Business Day following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth
in <U>Section 7</U>, <U>Section 8</U> and <U>Section 9</U>, other than those conditions that by their nature are to be satisfied at the
Closing, but subject to the satisfaction or waiver of each of such conditions), or at such other time, date and place as Parent and the
Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the &ldquo;<B>Closing Date</B>.&rdquo;
Prior to the Closing Date, Parent shall (i) create the Parent Convertible Preferred Shares and file the requisite notice of alteration
with the British Columbia Registrar of Companies in respect thereof and amend the articles of Parent to include the special rights or
restrictions attached to the Parent Convertible Preferred Shares (the &ldquo;<B>First Parent Charter Amendment</B>&rdquo;), (ii) in accordance
with <U>Section 6.3</U>, take all action necessary under applicable Law (including Canadian Securities Laws) to call, give notice of and
hold the Parent Shareholder Meeting to seek approval of the Parent Shareholder Matters, and (iii) take all steps necessary to promptly
obtain an authorization from the British Columbia Registrar of Companies to continue Parent out of the Province of British Columbia to
Nevada (which, for the avoidance of doubt, shall be the jurisdiction that is specified in the Continuation Resolution) (the &ldquo;<B>Continuation
Authorization</B>&rdquo;). Immediately prior to the Closing Date, and, for certainty, prior to the continuation contemplated by the immediately
following sentence, Parent shall (x) adopt a resolution of the Parent Board in accordance with Parent's Organizational Documents to change
the name of Parent to &ldquo;Mentari Therapeutics, Inc.&rdquo;, and (y) file a notice of alteration with the British Columbia Registrar
of Companies to change the name of Parent to &ldquo;Mentari Therapeutics, Inc.&rdquo; (clauses (x) and (y), the &ldquo;<B>Parent Name
Change</B>&rdquo;). On the Closing Date, following the completion of the Parent Name Change and the issuance of CVRs pursuant to Section
2.9, and prior to the filing of the First Certificate of Merger (as defined below), Parent shall take all actions that may be necessary
to continue Parent out of the Province of British Columbia to Nevada (the &ldquo;<B>Continuation</B>&rdquo;). At the Closing, (i) the
Parties shall cause the First Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a
certificate of merger with respect to the Merger, satisfying the applicable requirements of the DGCL and in form and substance attached
hereto as Exhibit D-1 and incorporated herein by reference (the &ldquo;<B>First Certificate of Merger</B>&rdquo;) and (ii) the Parties
shall cause the Second Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate
of merger with respect to the Second Merger, satisfying the applicable requirements of the DGCL and the DLLCA and in form and substance
attached hereto as Exhibit D-2 and incorporated herein by reference (the &ldquo;<B>Second Certificate of Merger</B>&rdquo; and together
with the First Certificate of Merger, the &ldquo;<B>Certificate of Merger</B>&rdquo;). The First Merger shall become effective at the
time of the filing of such Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be
specified in such Certificate of Merger with the consent of Parent and the Company (the time as of which the Merger becomes effective
being referred to as the &ldquo;<B>First Effective Time</B>&rdquo;). The Second Merger shall become effective at the time of the filing
of such Second Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in
such Second Certificate of Merger with the consent of Parent and the Company (the time as of which the Second Merger becomes effective
being referred to as the &ldquo;<B>Second Effective Time</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.2.3</TD><TD STYLE="text-align: justify"><U>Section 2.4(b)(iii)</U> of the Merger Agreement shall be, and hereby is, amended and replaced in its
entirety with the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">(iii) The Organizational Documents
of Parent shall be identical to the Organizational Documents of Parent immediately prior to the Second Effective Time; provided, however,
that immediately prior to the Second Effective Time, Parent shall adopt a resolution of the Parent Board in accordance with Parent's Organizational
Documents to (A) appoint new directors of Parent in accordance with subclause (b)(iv) below, and (B) make such other changes as are mutually
agreeable to Parent and the Company (such resolution, together with the Parent Name Change and the continuation of Parent from the Province
of British Columbia to Nevada and the First Parent Charter Amendment, the &ldquo;<B>Parent Charter Amendment</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.2.4</TD><TD STYLE="text-align: justify"><U>Section 2.11</U> of the Merger Agreement shall be, and hereby is, amended and replaced in its entirety
with the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">2.11&nbsp;<U>Intended
Tax Treatment</U>. The Parties acknowledge and agree that, for U.S. federal (and applicable state and local) income Tax purposes, (i)
the First Merger and the Second Merger, taken together, are intended to constitute an integrated transaction described in Rev. Rul. 2001-46,
2001-2 C.B. 321 that qualifies as a &ldquo;reorganization&rdquo; within the meaning of Section 368(a) of the Code, and (ii) Section 367
of the Code shall not apply to the Merger (the &ldquo;Intended Tax Treatment&rdquo;). The Parties adopt this Agreement as a &ldquo;plan
of reorganization&rdquo; within the meaning of Treasury Regulations Sections 1.368-2(g) and 1.368-3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.2.5</TD><TD STYLE="text-align: justify">References to &ldquo;Parent,&rdquo; &ldquo;Parent Common Shares,&rdquo; &ldquo;Parent Convertible Preferred
Shares,&rdquo; &ldquo;Parent Outstanding Shares&rdquo; and other similar terms shall be deemed to include references to Parent, and to
the corresponding shares and other attributes of Parent, in each case as they exist following the Continuation, <I>mutatis mutandis</I>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: -0.25in"><FONT STYLE="text-transform: uppercase"><B>Article
2&#9;Miscellaneous</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.1.&nbsp;Except
as specifically modified herein, the Merger Agreement remains in full force and effect, and the Parties hereto reserve all of their respective
rights and remedies with respect to all other matters and claims, whether known or unknown, arising under the Merger Agreement. On and
after the date hereof, each reference to the Merger Agreement in the Merger Agreement or any other document or instrument delivered in
connection therewith shall mean the Merger Agreement as amended by this Amendment. The Merger Agreement (including as amended hereby)
and the other schedules, exhibits, certificates, instruments and agreements referred to in the Merger Agreement constitute the entire
agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect
to the subject matter hereof and thereof; provided, however, that the Confidentiality Agreement shall not be superseded and shall remain
in full force and effect in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.2.&nbsp;This
Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument, with the same effect as if the signatures thereto were in the same instrument. The exchange of a fully executed
Amendment (in counterparts or otherwise) by all Parties by electronic transmission in PDF format shall be sufficient to bind the Parties
to the terms and conditions of this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.3.&nbsp;Article
11 of the Merger Agreement is hereby incorporated by reference into this Amendment, <I>mutatis mutandis</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: -0.25in">[<I>Signature
Pages Follow</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: -0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-variant: small-caps"><B>In Witness
Whereof</B></FONT><B>,</B> the Parties have caused this Amendment to be executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>InMed Pharmaceuticals Inc.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt"><B>INDIGO <FONT STYLE="text-transform: uppercase">MERGER SUB CORP.</FONT></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt"><B>INDIGO <FONT STYLE="text-transform: uppercase">MERGER SUB II, LLC</FONT></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Signature Page to Amendment No. 1</I>]</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-variant: small-caps"><B>In Witness
Whereof</B></FONT><B>,</B> the Parties have caused this Amendment to be executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Mentari Therapeutics, Inc.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page to Amendment No. 1</I>]</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">6</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ea029728401ex99-1.htm
<DESCRIPTION>PRESS RELEASE, ISSUED ON JULY 6, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
99.1</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">InMed
Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vancouver, British Columbia and San Francisco,
California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) (&ldquo;InMed&rdquo; or the &ldquo;Company&rdquo;)
today announced that it has entered into an amendment (the &ldquo;Amendment&rdquo;) to the previously announced definitive merger agreement
(the &ldquo;Agreement&rdquo;) for an all-stock transaction with Mentari Therapeutics, Inc. (&ldquo;Mentari&rdquo;), a privately-held biotechnology
company developing therapies for migraine prevention, Indigo Merger Sub Corp., a wholly-owned subsidiary of InMed, and Indigo Merger Sub
<B>I</B>, LLC, a wholly-owned subsidiary of InMed. InMed also announced that it has filed a registration statement on Form S-4 (the &ldquo;S-4&rdquo;)
with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) containing a preliminary proxy statement/prospectus and management
information circular in connection with the proposed merger (as amended, the &ldquo;Merger&rdquo;) and related transactions contemplated
by the Agreement (the Merger together with such related transactions, the &ldquo;Contemplated Transactions&rdquo;).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amendment to the Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Amendment, among other things, (i) clarifies
the sequencing of the Contemplated Transactions, (ii) reflects clarifications regarding the impact of the pre-closing financing on the
exchange ratio , and (iii) clarifies the intended tax treatment of the Merger. Except as specifically modified by the Amendment, the Agreement
remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Merger has received approval by the Boards
of Directors of InMed and Mentari and is expected to close in the fourth quarter of 2026, subject to certain closing conditions, including,
among others, approval by the shareholders of InMed and the stockholders of Mentari, the effectiveness of the S-4, and the satisfaction
of other customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For further information regarding the Merger,
refer to the Company&rsquo;s press release dated May 19, 2026.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Filing of Registration Statement on Form
S-4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">InMed filed on July 2, 2026 the S-4 containing
a preliminary proxy statement/prospectus and management information circular with the SEC in connection with the Merger. The S-4 outlines
the strategic rationale and merits of the Merger, as well as the processes undertaken by InMed and Mentari and their respective Boards
of Directors in reaching their recommendations. While the S-4 has not yet become effective and the information contained therein is subject
to change (including in respect of the Amendment), it provides important information about the Contemplated Transactions. Once declared
effective by the SEC, a date for a special meeting for InMed shareholders to approve the proposals associated with the transaction will
be set, and the definitive proxy statement/prospectus and management information circular will be mailed to InMed shareholders prior to
the vote. The S-4 is available through the SEC&rsquo;s EDGAR system at www.sec.gov and the preliminary proxy statement/prospectus and management
information circular contained therein will also be available on the System for Electronic Document Analysis and Retrieval + (SEDAR+).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">About InMed Pharmaceuticals</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">InMed is a pharmaceutical company focused on developing
a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed&rsquo;s pipeline consists of three separate
programs in the treatment of Alzheimer&rsquo;s, ocular and dermatological indications. For more information, visit www.inmedpharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">About Mentari Therapeutics</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mentari Therapeutics is a biotechnology company
developing therapies for the prevention of migraine to deliver freedom from this debilitating and undertreated neurological condition
that affects more than 1 billion people globally. Mentari&rsquo;s lead programs target PACAP, a newly validated target that is mechanistically
independent from CGRP, one of the first migraine targets to yield clinical and commercial success. Mentari&rsquo;s pipeline includes MT-001,
an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing, and MT-002, an anti-CGRP and anti-PACAP bispecific antibody
designed to inhibit these complementary pathways with potential to deliver superior outcomes for people with incomplete response to CGRP-targeted
therapies. The company&rsquo;s programs were discovered by Paragon Therapeutics. Mentari is based in Waltham, MA. For more information, visit
mentaritx.com.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Forward-Looking Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain statements in this press release,
other than purely historical information, may constitute &ldquo;forward- looking statements&rdquo; within the meaning of the federal
securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform
Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to
InMed&rsquo;s and Mentari&rsquo;s expectations, hopes, beliefs, intentions or strategies regarding the Merger, the Private
Placement, and the combined company&rsquo;s future, pipeline and business including, without limitation, statements regarding the
expected timing and completion of the Merger and the Private Placement, the expected benefits, opportunities and market potential of
the Merger and the effectiveness of the S-4 and the timing of the special meeting of InMed shareholders. In addition, any statements
that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying
assumptions, are forward-looking statements. These forward- looking statements are based on current expectations and beliefs
concerning future developments and their potential effects. There can be no assurance that future developments affecting the
combined company will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties
(some of which are beyond InMed&rsquo;s, Mentari&rsquo;s or the combined company&rsquo;s control) or other assumptions that may
cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, but are not limited to, risks related to: the risk that the Merger and the Private Placement
may not be completed on the anticipated timeline or at all; the failure to satisfy the conditions to closing, including obtaining
the requisite approvals of the shareholders of InMed and stockholders of Mentari and the effectiveness of the S-4 filed with the SEC
in connection with the Merger; the risk that the Private Placement may not close or may not result in the anticipated gross
proceeds; the outcome of preclinical studies and clinical trials; regulatory approval processes; the combined company&rsquo;s
ability to successfully develop and commercialize its product candidates; competition in the migraine treatment market; the combined
company&rsquo;s reliance on third parties; protection of intellectual property; and the combined company&rsquo;s need for
substantial additional funding. Should one or more of these risks or uncertainties materialize, or should any of InMed&rsquo;s,
Mentari&rsquo;s or the combined company&rsquo;s assumptions prove incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person
that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such
forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press
release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements
herein and in InMed&rsquo;s filings with the SEC. InMed, Mentari and the combined company do not undertake or accept any duty to
make any updates or revisions to any forward-looking statements, except as required by law.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Important Information About Investigational
Product Candidates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release concerns drug candidates
that are under preclinical and clinical investigation, and which have not yet been approved by the U.S. Food and Drug
Administration. These are currently limited by federal law to investigational use, and no representation is made as to their safety
or effectiveness for the purposes for which they are being investigated.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No Offer or Solicitation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release is not intended to and does
not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any proxy, vote, consent or
approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such jurisdiction. The securities to be sold in the Private Placement
are being offered in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended,
or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from
the registration requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION
HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Important Additional Information About the
Proposed Transaction</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Merger, InMed has filed
the S-4 with the SEC that contains a preliminary proxy statement/prospectus and management information circular relating to the Merger,
which has not yet been declared effective. This press release is not a substitute for the S-4, proxy statement/prospectus and management
information circular or any other document that InMed may file with the SEC in connection with the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">INVESTORS AND SECURITY HOLDERS OF INMED AND MENTARI
ARE URGED TO READ THE S- 4, PROXY STATEMENT/PROSPECTUS AND MANAGEMENT INFORMATION CIRCULAR AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO
BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE,
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT INMED, MENTARI, THE MERGER AND RELATED MATTERS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors and security holders will be able to
obtain free copies of the S-4, proxy statement/prospectus and management information circular and other documents filed by InMed with
the SEC through the website maintained by the SEC at www.sec.gov and on the Investors section of InMed&rsquo;s website.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Participants in the Solicitation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">InMed, Mentari and their respective directors
and executive officers may be deemed to be participants in the solicitation of proxies from InMed&rsquo;s shareholders in connection with the
Merger. Information about InMed&rsquo;s directors and executive officers, including a description of their interests in InMed, is contained
in InMed&rsquo;s most recent Annual Report on Form 10-K and subsequent reports filed with the SEC and certain Canadian securities regulators.
Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies
in connection with the Merger, including a description of their direct or indirect interests, by security holdings or otherwise, is included
in the S-4 and proxy statement/prospectus filed with the SEC, which has not yet been declared effective.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Media Contact</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lia Dangelico</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deerfield Group</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">lia.dangelico@deerfieldgroup.com</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Contact</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Colin Clancy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vice President, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and Corporate Communications, InMed Pharmaceuticals
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">T: +1.604.416.0999</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">E: ir@inmedpharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ea029728401_ex99-1img1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To view the source version
of this press release, please visit</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">https://www.newsfilecorp.com/release/304152</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">4</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ea029728401_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029728401_ex99-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !> +L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^Q+]KSXH^
M,]+M? _P ^#VJ'2OC;^T%K-SX>T+6[<-<S_#GP!9 7OQ!^*-TBYQ_P (YHFZ
MQTE?[0TUWU:]C;1GW:5MKD]&_P""9O['UG9QIK_PRO?B%K_S3:SXO\<>,/&.
MJ^*?$>H?\O6J:M=C7--T\WVH8RXT[3M-TP\[54%0'?L@>']8^)FM^-OVT_'>
MF7EEX@^-%I;Z'\(= O(5-[X*_9XTF[:\\$Z5M))L[_QM?!O'VL?\3!M++ZAI
MVQ=.PX7]!F4 '/&<<]3[>OK].<=Z]3$8C$Y;_L.%Q#PO7'\C:<\<EHKQE:4<
M&[Q2NTWS25GJO$HX3#9E_MN*PZQ27^X<VEHV\[6;[NQ\+_\ #M;]B;8<_ CP
M_P"N[^V/&''?&1KQY_#IWKXT_:)O?^'4O]C_ !<^"UMJ^I_ OXEZG_PJ;4_@
MCJ_B/4]5\-^%OC/XP.WX4^,?"8UJ_.HV.B:CKBWFG_$,?VF/^)21JZDE--_L
MK]L)ID@1YI942.,'S-YX..Q)./U/Z&OXT/\ @N=_P40^(ND>-_"VF_ KX4>*
M_CEIOASQOK'@_1M&T#P)XG\;^%9='T<+8_&WQ1=7FBZ'J=C::YXAOOL?P@^'
M^H$EO"W_ !/_ (B:,1JX U+TLA^OYGB^7%XBIB\MM_M[?M))V;44F[KGYN5Q
M:?,FK['G9I1P& P[^IT(83,FO]AUBO\ %>SV<>9/3KH?T%>!/^"<OP=UG0-.
M\3_M+:;>?'OXXZ_9VU]XZ\;^+/%?BB;3X=8O2UY>:'X2TNQO]-T[2/"VF7MR
MVFZ3$NEJXTP?.55UTU?0?^':?[$G_1!M _\ !YXQ_P#FJKQ__@F'^U3IGQY^
M!6E^'-3N-8B\3^ M \,76E6GB[3[SP[XSU?X8>)+0WGP_O-?\/ZL-/U&SU_3
MM/M;WP=XI^WKN_M?PX=6U9O^)K7ZFD  %<#GJ3QW^H_^O7'C\5FV Q->C4QV
M/C9M12E.,>1:1Y4K>ZX*-HV:BM.AUX# Y;B,-0J?4< Y6O)Z-J7VF]VFY7>O
M_#_E!\7OV6-*_9$TQ/VD/V1-$UOPM=_#>[M]>^*?PCTSQ-KM]X0^*_PRLL#Q
M7;'2=;O=46R\6:;HH.HZ/J.G< V=[C2=6U@Z7C])? OCKPU\2/"'AGQWX0U)
M-4\,>+M"L-?T+4(\C[9IVKVB7=HR[L?9KH(X#V9)V-Q@$$+V,L22I(CD.D@^
M;.2.#[X_^M]>:_.7]GR1_P!F/X_^*?V2K@2P?#'XAQ>(OB[^S))(&%MHT NQ
M=_$_X.V@8*?^*=OKD^+]%M A']D7U^^K:JVJM@\U2O5S'#OVK>)Q6$5^9N[^
MH];MKF?)>Z;;M%M:12MTTZ%++,3:E987%O9.Z^O=/1-=/+J?I/1117G'L!11
M10 4444 %%%% !1110 4444 %%%% !1110!\'?L.>.=1N?AE>?L^^-K.#2OB
MK^R[+HWPB\9:5;#$&I>'M&TP#X:>/-+W8OO["\9^$[6TU#2[]OG.IV>H[0#&
M*^YBR*N]AVSCD@@\D=N<\CD9[5^=?[4^D7_P$^(W@K]M/P78W=W8>$[:#P!^
MT=H>GVS7%QXC^!^LZE_R-(M3G[;KGPKUPVWB#,834M2TAK^+5M6TS1M+R=/]
MJ'XYR>-? 7P[^$7[/GC/2+_Q]^U?=7_A?P1XW\/ZG;7EGX6^'-GIGV[XF_%"
MUO;&^"$>'?"QNAI035-+U0ZO>6/]D$ZQIVT>G7PGU[$T<3AK>PQ>LM';!R5W
MCKNTG;1RC=M\K2O='@X?%K"8:OAL2TL3A-$WLT],':S2UT3L><6?@JP_;[^+
M/C?Q5XYOM9U/]D_X2:\? GPP\$:?KNJZ9X=^,WQ T:Y+>-_B?KT^B7VG'6_"
MWAW6EM?#WA%5U+5=+U8V6HMC36_M72M6_'_X]?LGWG[,'Q!\3?!?X+_#WP=I
M-A<^,=8^)?@ZS_L>ZN(/%7PX\>:I_I>JW5W>WVI'[=\&M;^U:!XK) /_  BE
M[I_B_60-(TW^U!_3U\+O O@KX1_#_P '_#7P5'9Z7X8\'Z%;:+H]EYEN)S;6
MF[=>7;)_Q^W^H7@NM1U74&&=5U2ZOM4)!D!'Y*?\%/K#5?VF;[X>_L^_L[FS
M\1_'WP)=:U\3_%NL>&]3'VGPC\'](M[.T\?_  OU>[L<FRO?VA=-N[/P8-!)
M)?\ T$ZVL>D:AI>J'Z;AG.,3EN9N$(O^S&G%J<>6,5%.V,?-%14KK6\KOGLK
M\L4>'GV6X;%8%5*DKYGHTXRO:]MDF]+-VTZ>K//?V+/^"=GP-^-6C>/_ -H#
MXC> [-+SQ_8^%O!'PV\8>%WU_P $>*;S1OAQ]MLKKXGVAL== L3XA\5_:M1\
M*:?J.F$Z1I&CZ>6_M-=3!K]$OV1?B+XRTW4/B#^RW\8M<O-;^+7P+NH!H_BW
M4]HO_BG\']:;/P_\> C_ (_-0L;/'A[Q85.IG2]5M+$ZQK&IZUJ.I&O6_P!F
MGXL?"?XK?"#P7KWPHNM)LO"MIX>T?2XO",%W:07OP\N-)M+6S_X0/5M(4#^Q
MKWPV;5=."$!0MH)-(+:7_9S'PC]LGP[JWA0^#/VP?AC:I/\ $+]G0ZC?^,=#
MCN+2V/Q'^!-V3_PLSP;=W1)S?:98"Z\8>$FU#*Z7JUE?D:4=6U-0/,S''8[-
M\=BX8U2:G)K+TT[8.2O&,4^6RC-)*5KIN2E>^KZL'A<+E."PV(P\U[JC_:&J
M;QJT;T<G9Q=]+*]K'Z$*=R=.#DGV'3VY/.>/Y5^;F@*_[2/[<5MX_P!'W'X9
M_L4VWC?P%I7B"*'_ )&_XW_$C0;/2/B#I-G=X NM-\%>%/LFG:K@!O\ A*>[
M:8V6ZC]HO]J_3;'X5^$=)^ VMZ7XK^-/[1=AH&F? C1[>1Q=A/&,-J4^(NK6
M;[[[1O"_AO0;J\UYM2U#3O[+&JV0TK5U16U%5^A_V>_@WX:^ ?PF\'?"OPW/
M)?VWAJRQJ>L7,6+_ ,1^(+RZ^V^(?$NJY'S7^HZW=7>HG!(TU2-,5MNG"O)A
M3G@,/7JU$UB<3?!135FHZK%RLTGM?#1TWD[/2YZ\JE/,\1AH4W_LV%MCI6V<
MK+ZHKJ_6[:OIU7;WRBBBO//9"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@+F->V-IJ-K<6-];07EE=PS6MQ;W$0G@NK>Z!6ZMKFV/'*G!SG(."/O _BI^
MVG_P3W_9B^'^M?#?]J[0?V?] O\ 2/A!K.LQ?&3P9X>&NV$&H_![QV;*T\5:
M[H&D:-KFFV%C?_#R[M+/Q!I>GZ<-*TK^RAJ/]L;-'TY5K]P0@[\_GQ6'J6E6
M&NZ=?:5JMK!J.FZA:W&F7^GZA:">RN[&]M_LEW:7=M=DB\LKU=RE2") VTL1
MOSU8'&XC!5>>GB&D]&DVKJ2<7LUK:6CTLTG?1'FX_ 8;'8=TZF'U3OV;:U2=
MG=K17O?K:VQ\%Z'_ ,$YOV"/$^CZ/KV@?!?PWJ^A:WIFGZGH^IZ?XQ\=SV6I
M:=>VOVNTNK2['BK_ $RQU&RN]P."I7L20P^G_A'\ ?@Y\!--NM(^$GP^\/\
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M%?V7]/NOVA/BKXX_;2\1V%[!X>U&UNOAK^S!X=U&$P#2/A1I5Y_Q./B.;6[
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M^U#KW[#?Q+U:YTWX7?M/W8U7X?QZG*;>R\+?M#Z-IFZT -ZRBQ_X7-X6L_\
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M%F.*HT$\4L>U%RLTDVWU=NJ[7LE>U[YUL0Y_5J52ZPUE=1O?1+=);?(_5_\
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M.SOS*,HN-FEUVMINSBX=RC'8/*7AJV'MB7F+G;R;OS;VVZG]>2@%?KZ'_/\
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M0VW@SP[^TYXLT?PE;1?9K:+1_P!NOXH:5X/@MR 1:VNCV5]_:(LB#T_LSO\
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MJOAO[5!+(/C?^U;\4OB;8V9'_+U::18V'C8_;N,<]^YS7V3X%_X--/BYX?\
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D96V2L[WV?YZ)[?\ !*%=>U]?7_+I\C^A:BBBN([PHHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>inm-20260706.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qRZo7xRiXhun8uNbXQsSaqHuaPtypR1OYkxs2t6HblKTyom7yY43CvvKbU24bsA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:srt-types="http://fasb.org/srt-types/2026" xmlns:INM="http://inmedpharma.com/20260706" elementFormDefault="qualified" targetNamespace="http://inmedpharma.com/20260706">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://inmedpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="inm-20260706_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="inm-20260706_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd" />
    <import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd" />
    <import namespace="http://fasb.org/us-types/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2026" schemaLocation="https://xbrl.sec.gov/country/2026/country-2026.xsd" />
    <import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd" />
    <import namespace="http://fasb.org/srt-types/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>inm-20260706_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>inm-20260706_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="inm-20260706.xsd#Cover" roleURI="http://inmedpharma.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://inmedpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 06, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  06,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INMED PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001728328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1428279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Suite 1445 &#8211; 885 West Georgia St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vancouver<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V6C 3E8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">669-7207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ea0297284-8k425_inmed.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://inmedpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0297284-8k425_inmed.htm">ea0297284-8k425_inmed.htm</File>
    <File>inm-20260706.xsd</File>
    <File>inm-20260706_lab.xml</File>
    <File>inm-20260706_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0297284-8k425_inmed.htm": {
   "nsprefix": "INM",
   "nsuri": "http://inmedpharma.com/20260706",
   "dts": {
    "inline": {
     "local": [
      "ea0297284-8k425_inmed.htm"
     ]
    },
    "schema": {
     "local": [
      "inm-20260706.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "inm-20260706_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "inm-20260706_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2026": 22
   },
   "report": {
    "R1": {
     "role": "http://inmedpharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-07-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0297284-8k425_inmed.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-07-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0297284-8k425_inmed.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CountryRegion",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Extension",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12gTitle",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://inmedpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-26-077127-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-077127-xbrl.zip
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MU.FA=13[B#<>[GQ3MOR*>G*K"NFJ4C(O%<O_Y'*S]-YZ:(8M+PR8<0M8QBS
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MC2@,?!P6N4C27*2(@&MME(C42"-^X;L"L327$MZ^E%>*N-)*KX:O8P5,FUR
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M_M%=.#M_[WW[(+.,8OMIUNVP<T\GGPQC9@QSED%9J\?O0:!5N.<AV&)#8W8
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MC#P]^)42Q-(+&)8]2;F*5->WBU*^JG;-7ITG"69-I_U(W/S<<G/5Y+._0-/
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MX'G(RN0$$)_,JGUU@1<<"Y2S Y4J\5K5V:^2YZZ*)2V9RM-2 ;%DV"Z7VU!
M6'DDKT,X:% [.24[2\4A]W%&,<92Y7E?"2U!C %,EL:CK=91J6N71>Q??^5S
M>/Z["T:4LMBXOO*6*XN6%0\O,6F[LLIZ63T8\_ZO:SM@F,4Z^/22_JPE'>-\
MRM<T*F\X.BJ9TW:X\66O/WK;&RC\P4<N+Z\&JGM)7Y]V1WSE9M ?]7M#=7IU
M<=$?#OM7E\W&V^Y0=:^O!U?O>F<*+YSUAZL?7_NQ_)OT0&_4&UST+W&_3_?[
M,M[-9?^T.\*0"A=&@YO1V]<WY_0\;EZ?XYVMBPDK9M5=52CNDRPN\U[[;Y,J
MARJWP^CZCY7I6JXX6'Z;)HY();_:X6"F7.YDHOUGOQ;;?(JSTO&JGXWW7,W6
MJ9H_XKKB003##\7'@#_4<W'0<R7^5N'OGM-TN"E%\\@?MV1%B4X)-OE+T[]P
MS'I+3.[R76\XNAH N"[//#I]4&^OSL]ZN C4ZE]> )[H[D7O<M0=]$&O!SUU
M,WB#RZ,K->AUSP3:V@I[!;C[;P>3]/P.?AY>]TY'-S+#1?>R^X;O8.#75X,+
MP;G3_N#TYKP[X&<(9Z\8?0>]\]Z[+IX]NSJ]H9>&ZG7_7,!U=-5LG/3<S^^!
MUAY?6PHP_+YW?DY_TUA=O'DF;^.]X<TU,%1^I$EZHZN6.L62@+'G'UB _B7=
MZ0\4'NKC@0^$SG3C_=L>W_J@3GK XI[JONOVS[LGY[T6"7/:O1GVY/[[/N8_
MO8+",%C_XOIJ,.JNK;E[<G4S$O6VO&Y;O(B+'I0KNH &H$G2VPBA8K@M5L?Y
M#7T$P*T.83)+Y=L=95&2#WNG(#[<4.%37G!)/AM6_9;I;\(:/5/'!O_U;_F%
M SF_PUN&V-7Y\SL]YM8.?63G#H.O3O%O.H3N^D\K%=A5L;]>EG1#;UVPOZ9.
M!S6)RF*QWL)$<'/YN/Y=3.0_AJ&S=1$1[;#@&R#O)B17H,@TIK8W[#=R2<MB
M@_[64SUR"3Y"21V0NEG5>HZ;8QSU;.1;HOZ];UOJ@Y4K4)L74#NK0,<#P\PL
M*F="3,9Y,70B:W%:,W;U<06W+^NSSE.;\YEV_FHBH8;00!.#+#_+W]MM_Z>
M"S@%ETGI!7K$;NB02C'*G;@Z!5Q$!BE0)<,J.Y#4VZY0U(>_&Y2>CZ7?1$";
MV*KD>ED15P", M9JA__"WGZAK?L5FI?-X^9^XOY=;D:+8*R&S-PB\6</[@P5
MQ4S9RI==JAZN>024[V] 2WT]A=PV./R:9L>O6][7^/7_^QK_AQ8(:#4!?["(
M;'H[HN\Y%G1&'W<".M.GGNQ,ZVS"I^W?@!@NGGJZV 2=R*_M'Y&??$ISTUGO
M;0-(3Y6_9*%/N+[-GP1]L[/>P%[PCCA(PN63_T8NT#)UC1!O(CYQ6RIWP,4=
M4):GEH#( ?W*IY3../,O/RH2_U&@+W*M?0Q*YZO#)\]]1X?JE[W.R]T7G1=[
M+SN[!P<'3SUC[U"9[!]KWSEN!P ?]R_>J.'@]/=G.MC=/_BW_7]_L;OW/_KS
MP4%[S\RG>YV/B^DSU3T?_?[L>XGTG1J J;HU&$"8>T&_;.<6N8#_]2H;ON!0
M"ZF#\G<[3RW>+,\7]G!GA\H2B?L%>R'] C98WHZ3:.?7W1=[O^W_?5$>98IU
M 85B?KM-^K&F?K$I"1@@3VQ[OOD0V7]PFCL3Y3,2>_=?G]7>KO[BRTI2P*-M
MR B\5H@/NS^K?+@FY'?TWAWZ9;#RVV'IE\C^+U!+ P04    "  ]H.I<-OF_
M6B@#  #H"P  $    &EN;2TR,#(V,#<P-BYX<V2U5MMRVC 0?>],_T'UNY$-
M"6D()),ADX8)N1223-*7CFP+T$26'$GF\O>5?.-B($!;/\FK<\[N:G=E-R^F
M(05C+"3AK&6Y%<<"F/D\(&S8LI[[]F6_W>E8X.+\ZQ>@G^8WVP;7!-.@ :ZX
M;W?8@)^!>Q3B!OB!&19(<7$&7A"-C85?$XH%:/,PHEAAO9%Z:H!ZY1@!V]Y!
M]@6S@(OG7J>0'2D5R0:$D\FDPO@83;AXEQ6?A[L)]A52L2S4G*F3/;O1[XCT
M"S+\Z/WB)],>>1W%['M\[[W^E'WT<1.C1S6+>N[#V_M45E7]QJ.W3S,>GLS>
MCFKM\?C6>ZX>>?(R==F4_@B'".A:,-FR3'Y9>I-:A8LAK#J."U_ONOT$9Z7
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M\=M&GK$307>]4+24KKD K)IH&+*@Z+![ P&IY'X960C,TD0-8+V0M*7.3S<
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M?9> 9>HA1K YILPM 7:330J:FH!(L!H#:-AK\V=*O1 QE2.3P'3&8K+]A>S
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M;MGHM-QDQ"H-B)4N?P S.@05,3JEKA]XMON$XD661;BE%JEC;$"S!C,M74C
M0.9:M% 2J>LM-SQ#"XZ^I@1ECP1=EC]#5\\$7]3CZY=&HDB]$%&LREF,A0VA
M+K'S7QT!#;=^>Z2E# *D7GOP[Y!4$4B'.*;F5C(LZN=QN8E91M;@VP[](:X(
M&FI><]2G#X*F@29-IO*PYLEU'HA4I,]L1O7D]O 2KR%RO#*V&#06QC5%$(R
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MO]P7L=HM_P-02P$"% ,4    "  ]H.I<N@%$3"L@   ^I   &0
M    @ $     96$P,CDW,C@T+3AK-#(U7VEN;65D+FAT;5!+ 0(4 Q0    (
M #V@ZEQO!5$6U1<  -&7   4              "  6(@  !E83 R.3<R.#0P
M,65X,BTR+FAT;5!+ 0(4 Q0    ( #V@ZER/$D^ZJQ0  $M6   5
M      "  6DX  !E83 R.3<R.#0P,65X.3DM,2YH=&U02P$"% ,4    "  ]
MH.I<-OF_6B@#  #H"P  $               @ %'30  :6YM+3(P,C8P-S V
M+GAS9%!+ 0(4 Q0    ( #V@ZES7\ WT_0H  '^&   4              "
M 9U0  !I;FTM,C R-C W,#9?;&%B+GAM;%!+ 0(4 Q0    ( #V@ZEQ+J'$"
M6P<  -E7   4              "  <Q;  !I;FTM,C R-C W,#9?<')E+GAM
7;%!+!08     !@ & (X!  !98P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ea0297284-8k425_inmed_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="inm-20260706.xsd" xlink:type="simple"/>
    <context id="AsOf2026-07-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001728328</identifier>
        </entity>
        <period>
            <startDate>2026-07-06</startDate>
            <endDate>2026-07-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-07-06" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-07-06" id="Fact000004">0001728328</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-07-06" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-07-06" id="Fact000010">2026-07-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-07-06" id="Fact000011">INMED PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-07-06" id="Fact000012">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-07-06" id="Fact000013">001-39685</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-07-06" id="Fact000014">98-1428279</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-07-06" id="Fact000015">Suite 1445 &#x2013; 885 West Georgia St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-07-06" id="Fact000016">Vancouver</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="AsOf2026-07-06" id="Fact000017">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-07-06" id="Fact000018">V6C 3E8</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-07-06" id="Fact000019">604</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-07-06" id="Fact000020">669-7207</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-07-06" id="Fact000021">true</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-07-06" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-07-06" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-07-06" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-07-06" id="Fact000025">Common Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-07-06" id="Fact000026">INM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-07-06" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-07-06" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
